These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 34055932)

  • 41. Pulmonary hypertension is associated with worse survival in hypertrophic cardiomyopathy.
    Ong KC; Geske JB; Hebl VB; Nishimura RA; Schaff HV; Ackerman MJ; Klarich KW; Siontis KC; Coutinho T; Dearani JA; Ommen SR; Gersh BJ
    Eur Heart J Cardiovasc Imaging; 2016 Jun; 17(6):604-10. PubMed ID: 26922089
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mid-regional proatrial natriuretic peptide for predicting prognosis in hypertrophic cardiomyopathy.
    Bégué C; Mörner S; Brito D; Hengstenberg C; Cleland JGF; Arbustini E; Galve E; Wichter T; Richter A; Golmard JL; Bernard M; Dubourg O; Komajda M; Charron P; Isnard R
    Heart; 2020 Feb; 106(3):196-202. PubMed ID: 31350276
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Contemporary Natural History and Management of Nonobstructive Hypertrophic Cardiomyopathy.
    Maron MS; Rowin EJ; Olivotto I; Casey SA; Arretini A; Tomberli B; Garberich RF; Link MS; Chan RHM; Lesser JR; Maron BJ
    J Am Coll Cardiol; 2016 Mar; 67(12):1399-1409. PubMed ID: 27012399
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Machine Learning Methods for Identifying Atrial Fibrillation Cases and Their Predictors in Patients With Hypertrophic Cardiomyopathy: The HCM-AF-Risk Model.
    Bhattacharya M; Lu DY; Ventoulis I; Greenland GV; Yalcin H; Guan Y; Marine JE; Olgin JE; Zimmerman SL; Abraham TP; Abraham MR; Shatkay H
    CJC Open; 2021 Jun; 3(6):801-813. PubMed ID: 34169259
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Advanced heart failure with preserved systolic function in nonobstructive hypertrophic cardiomyopathy: under-recognized subset of candidates for heart transplant.
    Rowin EJ; Maron BJ; Kiernan MS; Casey SA; Feldman DS; Hryniewicz KM; Chan RH; Harris KM; Udelson JE; DeNofrio D; Roberts WC; Maron MS
    Circ Heart Fail; 2014 Nov; 7(6):967-75. PubMed ID: 25239116
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predictors of Long-Term Outcome in Children with Hypertrophic Cardiomyopathy.
    Ziółkowska L; Turska-Kmieć A; Petryka J; Kawalec W
    Pediatr Cardiol; 2016 Mar; 37(3):448-58. PubMed ID: 26526335
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hypertensive heart disease versus hypertrophic cardiomyopathy: multi-parametric cardiovascular magnetic resonance discriminators when end-diastolic wall thickness ≥ 15 mm.
    Rodrigues JC; Rohan S; Ghosh Dastidar A; Harries I; Lawton CB; Ratcliffe LE; Burchell AE; Hart EC; Hamilton MC; Paton JF; Nightingale AK; Manghat NE
    Eur Radiol; 2017 Mar; 27(3):1125-1135. PubMed ID: 27368925
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A machine learning-based risk stratification model for ventricular tachycardia and heart failure in hypertrophic cardiomyopathy.
    Smole T; Žunkovič B; Pičulin M; Kokalj E; Robnik-Šikonja M; Kukar M; Fotiadis DI; Pezoulas VC; Tachos NS; Barlocco F; Mazzarotto F; Popović D; Maier L; Velicki L; MacGowan GA; Olivotto I; Filipović N; Jakovljević DG; Bosnić Z
    Comput Biol Med; 2021 Aug; 135():104648. PubMed ID: 34280775
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Systolic function reserve using two-dimensional strain imaging in hypertrophic cardiomyopathy: comparison with essential hypertension.
    Badran HM; Faheem N; Ibrahim WA; Elnoamany MF; Elsedi M; Yacoub M
    J Am Soc Echocardiogr; 2013 Dec; 26(12):1397-406. PubMed ID: 24094559
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Myocardial perfusion, function, and dyssynchrony in patients with heart failure: baseline results from the single-photon emission computed tomography imaging ancillary study of the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION) Trial.
    Atchley AE; Kitzman DW; Whellan DJ; Iskandrian AE; Ellis SJ; Pagnanelli RA; Kao A; Abdul-Nour K; O'Connor CM; Ewald G; Kraus WE; Borges-Neto S;
    Am Heart J; 2009 Oct; 158(4 Suppl):S53-63. PubMed ID: 19782789
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biventricular pacing (cardiac resynchronization therapy): an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2005; 5(13):1-60. PubMed ID: 23074464
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of diabetes mellitus on the outcomes of subjects with hypertrophic cardiomyopathy: A nationwide cohort study.
    Lee HJ; Kim HK; Kim BS; Han KD; Rhee TM; Park JB; Lee H; Lee SP; Kim YJ
    Diabetes Res Clin Pract; 2022 Apr; 186():109838. PubMed ID: 35314254
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Transaortic Chordal Cutting: Mitral Valve Repair for Obstructive Hypertrophic Cardiomyopathy With Mild Septal Hypertrophy.
    Ferrazzi P; Spirito P; Iacovoni A; Calabrese A; Migliorati K; Simon C; Pentiricci S; Poggio D; Grillo M; Amigoni P; Iascone M; Mortara A; Maron BJ; Senni M; Bruzzi P
    J Am Coll Cardiol; 2015 Oct; 66(15):1687-96. PubMed ID: 26449139
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy.
    Melacini P; Basso C; Angelini A; Calore C; Bobbo F; Tokajuk B; Bellini N; Smaniotto G; Zucchetto M; Iliceto S; Thiene G; Maron BJ
    Eur Heart J; 2010 Sep; 31(17):2111-23. PubMed ID: 20513729
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term outcomes and left ventricular diastolic function of sarcomere mutation-positive and mutation-negative patients with hypertrophic cardiomyopathy: a prospective cohort study.
    Chen CJ; Su MM; Liao YC; Chang FL; Wu CK; Lin LY; Chen YS; Lin YH; Hwang JJ; Yu SL; Kao HL; Chen WJ; Lu TP; Shih CY; Yeh SS; Yang DH; Lai LP; Juang JJ
    Eur Heart J Cardiovasc Imaging; 2020 Nov; ():. PubMed ID: 33221870
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Survival Differences in Women and Men After Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy.
    Meghji Z; Nguyen A; Fatima B; Geske JB; Nishimura RA; Ommen SR; Lahr BD; Dearani JA; Schaff HV
    JAMA Cardiol; 2019 Mar; 4(3):237-245. PubMed ID: 30810698
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy.
    Rowin EJ; Hausvater A; Link MS; Abt P; Gionfriddo W; Wang W; Rastegar H; Estes NAM; Maron MS; Maron BJ
    Circulation; 2017 Dec; 136(25):2420-2436. PubMed ID: 28916640
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms.
    Autore C; Bernabò P; Barillà CS; Bruzzi P; Spirito P
    J Am Coll Cardiol; 2005 Apr; 45(7):1076-80. PubMed ID: 15808767
    [TBL] [Abstract][Full Text] [Related]  

  • 59. N-terminal protype-B natriuretic peptide and Doppler diastolic variables are incremental for risk stratification of patients with NYHA class I-II systolic heart failure.
    Dini FL; Fontanive P; Buralli S; Panicucci E; Andreini D; Conti U; De Tommasi SM
    Int J Cardiol; 2009 Aug; 136(2):144-50. PubMed ID: 18649955
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CMR findings in patients with hypertrophic cardiomyopathy and atrial fibrillation.
    Papavassiliu T; Germans T; Flüchter S; Doesch C; Suriyakamar A; Haghi D; Süselbeck T; Wolpert C; Dinter D; Schoenberg SO; van Rossum AC; Borggrefe M
    J Cardiovasc Magn Reson; 2009 Sep; 11(1):34. PubMed ID: 19740409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.